TGFB1 and cancer: One way or another, the secretion of the platelet-derived active form of PAI1 could be an important mechanism constraining the overactivation of deleterious TGF-β signalling in the pro-coagulant cancer microenvironment, which, if inhibited by antiplatelet/anticoagulant therapy, could drive CAT and cancer progression.